DaVitaDVAEarnings & Financial Report
DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
Revenue
$3.3B
Gross Profit
N/A
Operating Profit
$534.9M
Net Profit
$214.7M
Gross Margin
N/A
Operating Margin
16.4%
Net Margin
6.6%
YoY Growth
4.6%
EPS
$2.50
DaVita Q3 FY2024 Financial Summary
DaVita reported revenue of $3.3B (up 4.6% YoY) for Q3 FY2024, with a net profit of $214.7M (down 13.0% YoY) (6.6% margin).
Key Financial Metrics
| Total Revenue | $3.3B |
|---|---|
| Net Profit | $214.7M |
| Gross Margin | N/A |
| Operating Margin | 16.4% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
DaVita Q3 FY2024 revenue of $3.3B breaks down across 4 segments, led by US Dialysis And Related Lab Services at $2.9B (88.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| US Dialysis And Related Lab Services | $2.9B | 88.5% |
| Medicaidand Managed Medicaid | $216.7M | 6.6% |
| Other Government Payors | $86.7M | 2.7% |
| Other | $70.4M | 2.2% |
DaVita Revenue by Segment — Quarterly Trend
DaVita revenue by segment across the last 4 reported quarters, showing how each business line (such as US Dialysis And Related Lab Services and Medicaidand Managed Medicaid) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Medicaidand Managed Medicaid | — | $232.8M | $214.7M | $217.7M |
| Other Government Payors | — | $102.8M | $87.0M | $83.1M |
| Other | — | $200.0M | $110.2M | $155.9M |
DaVita Annual Revenue by Year
DaVita annual revenue history includes year-by-year totals (for example, 2025 revenue was $13.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $13.6B |
| 2024 | $12.8B |
DaVita Quarterly Revenue & Net Profit History
DaVita results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $3.6B | +12.3% | $234.2M | 6.5% |
| Q4 FY2025 | $3.6B | +9.9% | $234.2M | 6.5% |
| Q3 FY2025 | $3.4B | +4.8% | $150.3M | 4.4% |
| Q2 FY2025 | $3.4B | +6.1% | $199.3M | 5.9% |
| Q1 FY2025 | $3.2B | +5.0% | $162.9M | 5.1% |
| Q4 FY2024 | $3.3B | +4.7% | $259.3M | 7.9% |
| Q3 FY2024 | $3.3B | +4.6% | $214.7M | 6.6% |
| Q2 FY2024 | $3.2B | +6.2% | $222.7M | 7.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.19B | $3.26B | $3.29B | $3.22B | $3.38B | $3.42B | $3.62B | $3.62B |
| YoY Growth | 6.2% | 4.6% | 4.7% | 5.0% | 6.1% | 4.8% | 9.9% | 12.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $17.03B | $17.50B | $17.29B | $17.12B | $17.49B | $17.56B | $17.48B | $17.48B |
| Liabilities | $14.60B | $15.28B | $15.19B | $15.46B | $15.94B | $16.22B | $16.32B | $16.32B |
| Equity | $632.9M | $386.7M | $121.1M | $-267.1M | $-369.6M | $-571.9M | $-651.1M | $-651.1M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $798.8M | $810.4M | $547.6M | $180.0M | $324.2M | $841.5M | $540.7M |